2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network
— Deadline October 14, 2025.
The 2026 NMD4C/MDC Neuromuscular Fellowship Funding Competition is now open, offering early-career scientists the chance to receive salary support for postdoctoral studies in neuromuscular disease research. This annual competition, hosted by the Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC), aims to empower the next generation of researchers in building successful careers in neuromuscular disease research and clinical practice.
Key Details:
- Competition Opened: September 2nd, 2025
- Eligibility: Early-career scientists conducting postdoctoral studies in neuromuscular disease research.
- Funding: $40,000 over a one-year period.
- Application Deadline: October 14, 2025.
Eligibility and Selection Criteria
Eligibility and selection guidelines are available on our Neuromuscular Fellowship Funding Competition page with instructions on how to submit your application.
If you have any questions about the 2026 competition, please contact our Network Manager, Erin Beattie.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.